China’s New CACA Guideline Targets Adult Cancer Pain With a Holistic, Multidisciplinary Blueprint

Cancer pain affects nearly half of all patients living with the disease, yet it remains one of the most inconsistently treated conditions in modern oncology. A sweeping new guideline from the China Anti-Cancer Association (CACA), published in Holistic Integrative Oncology, now lays out a comprehensive, evidence-based framework for diagnosing and managing adult cancer pain from diagnosis through end-of-life care. Developed by the Cancer Pain Integration Therapy Professional Committee of the CACA, the document distills the latest international evidence into a patient-centered strategy built on holistic integrative medicine, aiming to standardize everything from pain assessment scales to minimally invasive analgesic procedures and opioid safety protocols.

The scale of the problem the guideline addresses is striking. According to a 2022 systematic review cited in the document, the overall prevalence of pain among cancer patients reaches 44.5 percent, with 30.6 percent experiencing moderate to severe pain. The incidence climbs to roughly 50.3 percent during active treatment, 35.8 percent after effective treatment, and 54.6 percent in advanced, metastatic, or end-stage disease. Under the International Classification of Diseases, 11th Revision, chronic cancer-related pain is formally defined as chronic pain caused by the primary tumor itself or by metastasis, encompassing both chronic cancer pain and chronic post-cancer treatment pain. Because pain profoundly affects physical, psychological, and social functioning, the guideline’s authors argue that its management is an integral component of comprehensive cancer treatment and can even influence survival outcomes.

At the heart of the guideline is the principle of holistic integrative medicine, a philosophy that transforms traditional multidisciplinary team approaches, known as MDT, into a fully integrated care model the authors call MDT-to-HIM. Rather than treating pain as an isolated symptom, this model assembles oncologists, palliative care specialists, pain physicians, surgeons, pharmacists, rehabilitation experts, nutritionists, traditional Chinese medicine practitioners, psychologists, and nurses into a dynamic, patient-centered team. The guideline recommends this collaborative model for patients whose pain is poorly controlled by drug therapy alone, those with intolerable adverse drug reactions, patients with bone metastasis-related pain, and those whose pain coexists with tumor-related complications such as malnutrition, gastrointestinal obstruction, or malignant intracranial hypertension.

Accurate assessment is positioned as the mandatory first step. The guideline prescribes ‘holistic’ and ‘routine, quantitative, and dynamic’ evaluation, recommending the Numerical Rating Scale and the Faces Pain Rating Scale for universal screening, while offering the Behavioral Pain Scale and the Critical Care Pain Observation Tool for patients who cannot self-report, such as those with cognitive impairment or at the end of life. Diagnosis should follow the ICD-11 hierarchical classification, distinguishing nociceptive pain, which affects roughly 59 percent of cancer patients, from neuropathic pain at about 19 percent, and mixed pain at about 20 percent. Nociceptive pain is further divided into somatic and visceral subtypes, each with distinct treatment implications. The guideline also formally defines the concept of a ‘pain crisis’ as new-onset or severe pain arising on a background of stable control, requiring immediate intervention.

Pharmacotherapy remains the backbone of cancer pain management, and the guideline notes that more than 80 percent of patients can achieve good relief through drugs alone. First-line regimens center on opioids, nonsteroidal anti-inflammatory drugs, and adjuvant analgesics such as calcium channel modulators and antidepressants. Notably, the document endorses pharmacogenomic testing, particularly CYP2D6 genotyping, to individualize prodrug therapy like codeine and avoid both poor efficacy and serious adverse reactions. For moderate pain, the guideline suggests that low-dose strong opioids may actually be preferable to weak opioids, given their lower nausea rates, lower cost, and comparable efficacy, though weak opioids carry a well-known ceiling effect. Acetaminophen in combination preparations should not exceed 2 grams daily because of hepatotoxicity risk.

Detailed dosing protocols form a major strength of the document. For opioid-naive patients, titration typically begins with 5 to 15 milligrams of oral morphine or an equivalent short-acting opioid, while opioid-tolerant patients start at 10 to 20 percent of their previous 24-hour total dose. Once stable control is achieved, patients convert to long-acting formulations with a rescue dose of short-acting opioid set at 10 to 20 percent of the daily total for breakthrough pain. Dose increases during maintenance follow pain intensity, ranging from 25 to 50 percent for mild pain up to 75 to 100 percent for severe pain measured on the numerical scale. The guideline also provides granular instructions for opioid rotation, noting that 20 to 44 percent of patients require a switch and that 40 to 80 percent improve analgesia afterward, with methadone conversions demanding reductions of 75 to 90 percent and, ideally, in-hospital supervision.

Safety receives extensive attention. The guideline catalogs management strategies for opioid-induced constipation, nausea and vomiting, pruritus, delirium, urinary retention, sedation, and respiratory depression, including precise naloxone dosing of 1 to 2 milliliters of a 0.4 milligram per 10 milliliter solution when respiratory rates fall below 8 breaths per minute. It also confronts the growing challenge of opioid misuse: prevalence estimates among long-term users range from 21 to 29 percent, and 8 to 12 percent of cancer patients on long-term opioids develop opioid use disorder. The document recommends validated screening tools such as the SOAPP-R and Opioid Risk Tool before initiating therapy, real-time monitoring with the Current Opioid Misuse Measure during treatment, urine drug testing, and prescription drug monitoring programs as pillars of risk mitigation.

When drugs fall short, the guideline opens the door to an arsenal of minimally invasive techniques that can be deployed before, during, or after standard three-step drug therapy. Patient-controlled analgesia via intravenous or subcutaneous routes offers rapid, individualized titration and can even be managed safely at home. Nerve blocks and neurolysis, particularly celiac plexus neurolysis with 75 to 100 percent ethanol, provide durable relief for refractory visceral pain. Percutaneous vertebroplasty stabilizes painful vertebral metastases, while spinal cord and peripheral nerve stimulation offer reversible neuromodulation for stable-tumor neuropathic pain. Perhaps most remarkable is intrathecal drug delivery, in which morphine infused directly into the cerebrospinal fluid is roughly 100 times more potent than the intravenous route and 300 times more potent than oral administration, dramatically reducing systemic doses and their side effects.

The guideline also integrates palliative antitumor therapies as analgesic tools, noting that a single 8-gray dose of radiotherapy relieves bone metastasis pain in about 40 percent of patients, while microwave and radiofrequency ablation can inactivate tumor tissue and reduce pain indirectly. Adjunctive approaches including traditional Chinese medicine, physical therapy, and structured psychological support such as mindfulness-based cognitive therapy and pain neuroscience education round out the multimodal framework. Ultimately, the authors identify the chief barriers to better care as outdated clinical concepts, restricted opioid access, nonstandard treatment, and weak multidisciplinary collaboration, and they express confidence that disseminating this guideline will extend both the quality of life and the survival of patients with cancer pain across China and beyond.

Subject of Research: Clinical practice guideline for the multidisciplinary management of adult cancer pain developed by the China Anti-Cancer Association

Article Title: CACA guidelines for the management of adult cancer pain

Article References: Jin, Y., Zhang, J., Suo, J., Yu, H., Song, L., Chen, F., Cheng, W., Cui, W., Fan, B., Feng, Z., Gong, L., Gu, N., Guo, L., Jia, Y., Li, S., Lin, F., Lin, R., Liu, B., Lu, G., … Xie, G. (2026). CACA guidelines for the management of adult cancer pain. Holistic Integrative Oncology, 5(1), Article 66. https://doi.org/10.1007/s44178-026-00286-5

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00286-5

Keywords: cancer pain, CACA guideline, opioid therapy, palliative care, intrathecal drug delivery, multidisciplinary team, holistic integrative medicine, breakthrough pain, bone metastasis, neuropathic pain, opioid rotation, patient-controlled analgesia